Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

The Yield and Safety of Skin Biopsies in Acute Myeloid Leukemia Patients during Intensive Chemotherapy Treatment

Tamar Berger, MD, Ofir Wolach, MD, Shany Sherman, MD, Adi Shacham Abulafia, MD, Pia Raanani, MD, Oren Pasvolsky, MD

Blood (2019) 134 (Supplement_1): 5110.

https://doi.org/10.1182/blood-2019-125133

Published: 2019

Journal Articles

Leukemia Cutis As an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia

Mahmood B Aldapt, MD, Mohamed A Yassin, MBBS, MSc

Blood (2019) 134 (Supplement_1): 5461.

https://doi.org/10.1182/blood-2019-121654

Published: 2019

Journal Articles

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Kamal Menghrajani, MD, Sheng F Cai, MD PhD, Sean M. Devlin, PhD, Scott A. Armstrong, MD PhD, Richard Piekarz, MD PhD MS, BA, Michelle Rudek, PharmD, PhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 2655.

https://doi.org/10.1182/blood-2019-121926

Published: 2019

Journal Articles

Extramedullary Manifestations in World Health Organization-Defined Chronic Myelomonocytic Leukemia: Clinical, Molecular and Prognostic Correlates

Katherine Hoversten, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Rhett P. Ketterling, MD, Curtis A. Hanson, MD, Naseema Gangat, MBBS, Ayalew Tefferi, MD, Mrinal M. Patnaik, MDMBBS

Blood (2017) 130 (Supplement 1): 4272.

https://doi.org/10.1182/blood.V130.Suppl_1.4272.4272

Published: 2017

Journal Articles

Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Blood (2017) 130 (Supplement 1): 275.

https://doi.org/10.1182/blood.V130.Suppl_1.275.275

Published: 2017

Journal Articles

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

Leslie A. Andritsos, MD, Mirela Anghelina, MD, Nicole R. Grieselhuber, MD PhD, Sameek Roychowdhury, MD PhD, Julie Reeser, PhD, Cynthia Timmers, PhD, Aharon G. Freud, MD PhD, James S. Blachly, MD, David M. Lucas, PhD, Gerard Lozanski, MD, Jeffrey Jones, MD MPH, Kerry A. Rogers, MD, Weiqiang Zhao, MD PhD, Michael R. Grever, MD

Blood (2016) 128 (22): 5598.

https://doi.org/10.1182/blood.V128.22.5598.5598

Published: 2016

Journal Articles

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Eytan M. Stein, MD, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Raoul Tibes, MD PhD, Jesus G. Berdeja, MD, Mojca Jongen-Lavrencic, MD PhD, Jessica K. Altman, MD, Hartmut Dohner, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Greg Fine, MS, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Bob Lowenberg, MD PhD, Martin S Tallman, MD

Blood (2015) 126 (23): 2547.

https://doi.org/10.1182/blood.V126.23.2547.2547

Published: 2015

Journal Articles

Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission

Fotios V. Michelis, MDPhD, Hans A. Messner, MD/PhD, Naheed Alam, MBBS,MD, Vikas Gupta, MD MRCP, FRCPath, Dennis Dong Hwan Kim, MD PhD, John Kuruvilla, MD, Anna Lambie, RN NP, Auro Viswabandya, MD DM, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 2020.

https://doi.org/10.1182/blood.V126.23.2020.2020

Published: 2015

Journal Articles

Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Elias Jabbour, Marina Konopleva, MD PhD, Miranda Lim, BSN, Sherry Pierce, BSN, BA, Susan O'Brien, MD, Bradley G. Somer, MD, Ana Tari, PhD, William Wierda, MD PhD, Srdan Verstovsek, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3801.

https://doi.org/10.1182/blood.V126.23.3801.3801

Published: 2015

Journal Articles

A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Matthew S. Davids, MD, Haesook T. Kim, PhD, Caitlin L. Costello, MD, Peter A. McSweeney, MD, Rebecca Liguori, Alexander Lukez, David Avigan, MD, Yi-Bin Chen, MD, Nicole LeBoeuf, Vincent T. Ho, MD, Corey S Cutler, MD MPH, John Koreth, MBBS, DPhil, Edwin P. Alyea, MD, Joseph H Antin, MD, Jerome Ritz, MD, Philippe Armand, MD PhD, Edward D Ball, MD, Asad Bashey, MD PhD, Robert J. Soiffer, MD

Blood (2015) 126 (23): 860.

https://doi.org/10.1182/blood.V126.23.860.860

Published: 2015

Journal Articles

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop Kantarjian, MD, Ghulam J. Mufti, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS, Jeffrey Szer, MB BS FRACP, Uwe Platzbecker, MD, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD PhD, Janet Franklin, MD MPH, Aristoteles Giagounidis, MD

Blood (2015) 126 (23): 2863.

https://doi.org/10.1182/blood.V126.23.2863.2863

Published: 2015

Journal Articles

The Addition of Radiation Therapy to Initial Treatment for Extramedullary Acute Myeloid Leukemia Does Not Offer a Survival Benefit When Added to Chemotherapy

Faye M. Feller, MD, Minal Patel, Sean M. Devlin, PhD, Molly Maloy, MA, Martin S. Tallman, MD, Miguel-Angel Perales, MD, Raajit K. Rampal, MD PhD

Blood (2014) 124 (21): 960.

https://doi.org/10.1182/blood.V124.21.960.960

Published: 2014

Journal Articles

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Blood (2014) 124 (21): 387.

https://doi.org/10.1182/blood.V124.21.387.387

Published: 2014

Journal Articles

Next Generation Sequencing (NGS) Identifies an Association Between NPM1 Mutation and Leukemia Cutis

Marlise R. Luskin, MD, Campbell L. Stewart, MD, Jennifer JD Morrissette, PhD, David Lieberman, MS, CGC, David J. Margolis, MD, Alexander E. Perl, MD, Misha A. Rosenbach, MD

Blood (2014) 124 (21): 2341.

https://doi.org/10.1182/blood.V124.21.2341.2341

Published: 2014

Journal Articles

Treatment with Romiplostim, a Thrombopoietin-Receptor Agonist, in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Updated Follow-up Results for Acute Myeloid Leukemia (AML) and Survival from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop M. Kantarjian, Ghulam Mufti, Pierre Fenaux, Mikkael Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Amelia Orejudos, Angela Lopez, Aristoteles Giagounidis

Blood (2014) 124 (21): 3276.

https://doi.org/10.1182/blood.V124.21.3276.3276

Published: 2014

Journal Articles

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Marina Konopleva, MD, PhD, Damian R Handisides, Mary Ann Richie, RN, Juliana M Benito, PhD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Stewart Kroll, Michael Andreeff, MD, PhD, Hagop M Kantarjian, MD, Deborah A. Thomas, MD

Blood (2013) 122 (21): 3920.

https://doi.org/10.1182/blood.V122.21.3920.3920

Published: 2013

Journal Articles

Sequencing-Based Minimal Residual Disease Assessment In T-Cell Malignancies: T-Cell Prolymphocytic Leukemia Case Study

Katherine Sutherland, Katherine Kong, Aaron C. Logan, MD, PhD, Malek Faham, MD, PhD, David B. Miklos, MD, PhD

Blood (2013) 122 (21): 1392.

https://doi.org/10.1182/blood.V122.21.1392.1392

Published: 2013

Journal Articles

Therapy-Related Myeloid Sarcoma As a New Diagnostic Entity? A 10-Year Institutional Retrospective Review

Taylor Deal, MD, Uma Borate, MD, Shuko Harada, MD, Vishnu Reddy, MD, Deniz Peker, MD

Blood (2013) 122 (21): 2656.

https://doi.org/10.1182/blood.V122.21.2656.2656

Published: 2013

Journal Articles

Safety, Pharmacokinetics, and Efficacy Of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) In Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Maro Ohanian, DO, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Michael Andreeff, MD, PhD, Elias Jabbour, MD, Marina Konopleva, MD, PhD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Bradley G. Somer, MD, Ana Tari, PhD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2679.

https://doi.org/10.1182/blood.V122.21.2679.2679

Published: 2013

Journal Articles

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Stephan A Grupp, MD, PhD, Noelle V. Frey, MD, Richard Aplenc, MD, PhD, David M Barrett, MD/PhD, Anne Chew, PhD, Michael Kalos, PhD, Bruce L. Levine, PhD, Manuel Litchman, MD, Shannon L Maude, MD, PhD, Susan R. Rheingold, Angela Shen, MD, Christine Strait, David T. Teachey, MD, Patricia A. Wood, MD, PhD, David Porter, MD, Carl H. June, MD

Blood (2013) 122 (21): 67.

https://doi.org/10.1182/blood.V122.21.67.67

Published: 2013

NARROW

The Yield and Safety of Skin Biopsies in Acute Myeloid Leukemia Patients during Intensive Chemotherapy Treatment

Leukemia Cutis As an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Extramedullary Manifestations in World Health Organization-Defined Chronic Myelomonocytic Leukemia: Clinical, Molecular and Prognostic Correlates

Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission

A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

The Addition of Radiation Therapy to Initial Treatment for Extramedullary Acute Myeloid Leukemia Does Not Offer a Survival Benefit When Added to Chemotherapy

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Next Generation Sequencing (NGS) Identifies an Association Between NPM1 Mutation and Leukemia Cutis

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Sequencing-Based Minimal Residual Disease Assessment In T-Cell Malignancies: T-Cell Prolymphocytic Leukemia Case Study

Therapy-Related Myeloid Sarcoma As a New Diagnostic Entity? A 10-Year Institutional Retrospective Review

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only